Potassium + Quinapril

What is happening. ACE inhibitors such as quinapril reduce aldosterone secretion, which decreases urinary potassium excretion and raises serum potassium. Adding supplemental potassium (or potassium-based salt substitutes) can produce clinically significant or dangerous hyperkalemia, particularly in patients with chronic kidney disease, diabetes, heart failure, or those also taking potassium-sparing diuretics, aldosterone antagonists, NSAIDs, or ARBs.

Mechanism. Quinapril inhibits angiotensin-converting enzyme, lowering angiotensin II and aldosterone, which reduces renal potassium excretion; exogenous potassium then accumulates, causing additive hyperkalemia.

Recommendation. Avoid routine potassium supplements and potassium-containing salt substitutes while taking quinapril unless prescribed and monitored. If supplementation is medically necessary, use the lowest effective dose with periodic serum potassium and renal function checks. Report symptoms such as muscle weakness, palpitations, or numbness.

What is happening. Potassium supplements or potassium-containing salt substitutes can cause hyperkalemia with Quinapril.

Mechanism. Renin-angiotensin system blockade reduces aldosterone-mediated potassium excretion.

Recommendation. Avoid unsupervised potassium supplementation; check potassium and kidney function after initiation, dose changes, or illness.